
The zzso inhibitor zzso (formerly zzso is a soluble form of zzso zzso zzso zzso that prevents zzso of zzso zzso by bone zzso zzso zzso and zzso and exhibits zzso activity in zzso zzso This zzso study of zzso evaluated its safety, zzso zzso zzso and zzso activity in adults with advanced solid zzso 

Patients in zzso zzso received zzso zzso at one of seven dose levels zzso zzso every 3 weeks until disease zzso Patients in an expansion cohort received zzso at zzso or zzso zzso every 3 weeks until disease zzso 

In 37 patients receiving zzso the most common zzso adverse events were peripheral zzso fatigue, and zzso zzso and fluid retention were zzso zzso and responded to zzso zzso No clinically zzso zzso hypertension, zzso gross zzso or gastrointestinal zzso were zzso One patient with zzso zzso cell cancer of the head and neck had a partial response, and 13 patients had stable disease according to zzso eight of whom had prolonged periods zzso weeks) of stable zzso zzso zzso markers included tumor zzso activity and tumor blood flow, which decreased from baseline in zzso and zzso of zzso patients, respectively, and zzso in eight zzso 

zzso was zzso at doses up to zzso zzso with a safety profile distinct from zzso of the zzso zzso zzso displayed promising zzso activity in patients with advanced zzso cancer, and multiple phase II studies are zzso 

